The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

EVERYONE’S talking about fat jabs – the ‘miracle’ injections trimming inches off waistlines, and helping turn the tide on the ...

Eli Lilly has morphed from a reliable pharma giant into a biotech powerhouse riding blockbuster success. Mounjaro and ...

The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

In the wake of early evidence supporting the long-term health benefits of GLP-1 based medications to potentially reduce the ...

Discover how the breakthrough pill orforglipron matches injectable weight loss drugs in effectiveness while offering ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill from Eli Lilly could be as effective for weight loss and blood sugar ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Is the pill for obesity coming? Pharmaceutical company Eli Lilly has released initial Phase 3 results for Orforglipron—the world’s first oral GLP-1 pill that significantly lowers blood sugar and ...